Company Profile for Immune-Onc Therapeutics, Inc.
--(BUSINESS WIRE)--Nov 21, 2019--
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com.
Immune-Onc Therapeutics, Inc.
795 San Antonio Road
Palo Alto, CA 94303
Type of Organization:
CEO: Charlene Liao
View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005345/en/
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Immune-Onc Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 11/21/2019 03:55 AM/DISC: 11/21/2019 03:55 AM